A critical systematic review of budget impact analyses on drugs in the EU countries

Applied Health Economics and Health Policy

Volumn 12, Issue 1, 2014, Pages 33-40

  Van De Vooren, Katelijne ^a   Duranti, Silvy ^a   Curto, Alessandro ^a   Garattini, Livio ^a  

^a CESAV   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUDGET; BUDGET IMPACT ANALYSIS; DRUG COST; DRUG INDUSTRY; ECONOMIC EVALUATION; HEALTH CARE POLICY; HUMAN; REVIEW; SYSTEMATIC REVIEW;

BIOMEDICAL RESEARCH; BUDGETS; COSTS AND COST ANALYSIS; DRUG COSTS; DRUG INDUSTRY; EUROPEAN UNION; HUMANS; RESEARCH SUPPORT AS TOPIC;

EID: 84893534896     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0064-7     Document Type: Review

References (33)

1. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics. 2001;19(6):609-21.
2. Mauskopf JA, Sullivan S, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health. 2007;10(5):336-47.
3. Marshall DA, Douglas PR, Drummond M, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics. 2008;26(6):477-95.
4. Orlewska E, Gulácsi L. Budget-impact analyses: a critical review of published studies. Pharmacoeconomics. 2009;27(10):807-27.
5. Garattini L, Van de Vooren K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ. 2011;12(6):499-502.
6. De Pouvourville G, Ulmann P, Nixon J, et al. The diffusion of health economics knowledge in Europe: the EURONHEED (European Network of Health Economic Evaluation Databases) Project. Pharmacoeconomics. 2005;23(2):113-20.
7. Mauskopf J. Prevalence-based economic evaluation. Value Health. 1998;1(4):251-9.
8. Atkins KE, Shim E, Carroll S, et al. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. Vaccine. 2012;30(48):6766-76.
9. Geitona M, Carayanni V, Petratos P. Economic evaluation of opioid substitution treatment in Greece. Heroin Addict Relat Clin Probl. 2012;14(3):77-88.
10. Fragoulakis V, Kourlaba G, Goumenos D, et al. Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece. Clin Econ Outcomes Res. 2012;4:127-34.
11. Bager P, Dahlerup JF. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohns Colitis. 2010;4(4):427-30.
12. Purmonen TT, Auvinen PK, Martikainen JA. Budget impact analysis of trastuzumab in early breast cancer: a hospital district perspective. Int J Technol Assess Health Care. 2010;26(2):163-9.
13. Cicchetti A, Ruggeri M, Gitto L, et al. Extending influenza vaccination to individuals aged 50-64: a budget impact analysis. Int J Technol Assess Health Care. 2010;26(3):288-93.
14. De Salas-Cansado M, Cuadros M, Del Cerro M, et al. Budget impact analysis in Spanish patients with Dupuytren's contracture: fasciectomy vs. collagenase Clostridium histolyticum. Chir Main. 2013. pii: S1297-3203(13)00032-2.
15. Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med. 2013. pii: S0954-6111(12)00506-9.
16. Gordon J, Evans M, McEwan P, et al. Evaluation of insulin use and value for money in type 2 diabetes in the United Kingdom. Diabetes Ther. 2013 (Epub ahead of print).
17. Jiang Y, Gauthier A, Annemans L, et al. A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany. Expert Rev Pharmacoecon Outcomes Res. 2012;12(5):631-43.
18. Avgerinou G, Bassukas I, Chaidemenos G, et al. Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece. BMC Dermatol. 2012;12:10.
19. Dee A, Hutchinson M, De La Harpe D. A budget impact analysis of natalizumab use in Ireland. Ir J Med Sci. 2012;181(2):199-204.
20. Thorlund K, Druyts E, El Khoury AC, Mills EJ. Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. Clinicoecon Outcomes Res. 2012;4:349-59.
21. Rønborg SM, Svendsen UG, Micheelsen JS, et al. Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis. Clinicoecon Outcomes Res. 2012;4:253-60.
22. Fragoulakis V, Kourlaba G, Maniadakis N. Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece. Clinicoecon Outcomes Res. 2012;4:135-43.
23. Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. Appl Health Econ Health Policy. 2011;9(4):217-23.
24. Guest JF, Concolino D, Di Vito R, et al. Modelling the resource implications of managing adults with Fabry disease in Italy. Eur J Clin Invest. 2011;41(7):710-8.
25. Guest JF, Jenssen T, Houge G, et al. Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. Eur J Clin Invest. 2010;40(12):1104-12.
26. Purmonen T, Nuttunen P, Vuorinen R, et al. Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta Oncol. 2010;49(6):837-43.
27. Gani R, Griffin J, Kelly S, Rutten-van Mölken M. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J. 2010;19(1):68-74.
28. Colin X, Lafuma A, Costagliola D, et al. Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France. Pharmacoeconomics. 2010;28(Suppl 1):183-97.
29. Taylor DCA, Chu P, Rosen VM, et al. Budgetary impact of varenicline in smoking cessation in the United Kingdom. Value Health. 2009;12(1):28-33.
30. Launois R, Payet S, Saidenberg-Kermanac'h N, et al. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine. 2008;75(6):688-95.
31. NICE. Methods guide. Assessing cost impact. http://www.nice.org.uk/media/ 99A/F8/Costing-Manual-update-050811.pdf (Accessed 20 Aug 2013).
32. Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care. 2010;26(3):330-3.
33. Drugs and devices look more effective in studies sponsored by industry. BMJ. 2012;345:e8386.